Last $5.39 HKD
Change Today 0.00 / 0.00%
Volume 734.0K
As of 4:01 AM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

microport scientific corp (853) Snapshot

Open
$5.44
Previous Close
$5.39
Day High
$5.45
Day Low
$5.37
52 Week High
07/2/13 - $6.65
52 Week Low
09/12/13 - $4.40
Market Cap
7.6B
Average Volume 10 Days
1.2M
EPS TTM
$0.11
Shares Outstanding
1.4B
EX-Date
06/27/14
P/E TM
39.3x
Dividend
--
Dividend Yield
1.48%
Current Stock Chart for MICROPORT SCIENTIFIC CORP (853)

Related News

No related news articles were found.

microport scientific corp (853) Related Businessweek News

No Related Businessweek News Found

microport scientific corp (853) Details

MicroPort Scientific Corporation, a medical technology company, through its subsidiaries, develops, manufactures, and sells interventional medical devices in the People’s Republic of China and internationally. It operates through seven segments: Cardiovascular Devices, Neurovascular Devices, Endovascular Devices, Electrophysiology Devices, Orthopedic Devices, Diabetes Care and Endocrinal Management, and Surgical Management. The Cardiovascular Devices segment offers therapies to treat coronary artery disease; and sells coronary stents and related delivery systems, as well as balloon catheters and accessories. The Neurovascular Devices segment provides medical devices to treat the central nervous system related vascular diseases. Its products include WILLIS, an intracranial stent graft system; and Tubridge, a revascularization device to treat large intracranial aneurysms. The Endovascular Devices segment offers products and therapies to treat abdominal and thoracic aortic aneurysms and peripheral vascular disease. It provides CRONUS, a surgical stent graft system; CROWNUS, a peripheral stent system; and other vascular stents to treat endovascular diseases and disorders. The Electrophysiology Devices segment offers minimally invasive medical devices for treating electrophysiological diseases. The Orthopedics Devices segment provides instruments and implants to treat orthopedic conditions. The Diabetes Care and Endocrinal Management segment primarily engages in developing, manufacturing, monitoring, and managing medical devices for the treatment of diabetes and endocrinal. The Surgical Management segment specializes in extracorporeal circulation and cardiovascular-related devices. Its products include membrane oxygenation system, Amender PDA Occluder, and Amender ASD Occluder. MicroPort Scientific Corporation was founded in 1998 and is headquartered in Shanghai, China.

1,896 Employees
Last Reported Date: 03/31/14
Founded in 1998

microport scientific corp (853) Top Compensated Officers

Founder, Chairman of the Board, Chief Executi...
Total Annual Compensation: CNY1.9M
President and Chairman of Executive Committee
Total Annual Compensation: CNY1.3M
Chief Financial Officer and Member of Executi...
Total Annual Compensation: CNY934.0K
Chief Technology Officer and Member of Execut...
Total Annual Compensation: CNY1.1M
Compensation as of Fiscal Year 2012.

microport scientific corp (853) Key Developments

ReFlow Medical, Inc. Signs Exclusive Distribution and Sales Agreement with MicroPort Scientific

ReFlow Medical, Inc. announced that it has signed an exclusive distribution and sales agreement for ReFlow's suite of peripheral chronic total occlusion (CTO) products with MicroPort Endovascular (MicroPort Endo), a division of MicroPort Scientific Corporation. ReFlow has developed a suite of products to cost-effectively address unmet needs in the CTO market. ReFlow's Wingman crossing catheter is 510(k) cleared and CE Marked to be used in conjunction with steerable guidewires to access discrete regions of the peripheral vasculature and enable rapid, routine, off-the-shelf lesion crossing.

MicroPort Scientific Corporation Recommends No Dividend for 2013; Announces Audited Consolidated Earnings Results for the Full Year Ended December 31, 2013

The Directors of MicroPort Scientific Corporation do not recommend the payment of an annual dividend for the year ended December 31, 2013. The company paid dividend of HKD 0.08 per share for 2012. The company announced audited consolidated earnings results for the full year ended December 31, 2013. For the year, the company reported revenue of RMB 938,682,000 against RMB 930,962,000 a year ago. Such increase was primarily attributable to the increase of the sales of non-cardiovascular devices. Profit for the year was RMB 148,531,000 against RMB 353,980,000 a year ago. Profit from operations was RMB 211,786,000 against RMB 417,033,000 a year ago. Profit before taxation was RMB 205,257,000 against RMB 415,358,000 a year ago. Earnings per diluted share were RMB 0.10 against RMB 0.25 a year ago. During the year, the group's total capital expenditure amounted to RMB 320.3 million, which was used in (i) building and purchasing lands and (ii) acquiring equipment and machinery and (iii) capitalization of R&D projects expenses.

MicroPort Scientific Corporation, 2013 Earnings Call, Apr 01, 2014

MicroPort Scientific Corporation, 2013 Earnings Call, Apr 01, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
853:HK $5.39 HKD 0.00

853 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 853.
View Industry Companies
 

Industry Analysis

853

Industry Average

Valuation 853 Industry Range
Price/Earnings 40.6x
Price/Sales 6.3x
Price/Book 2.5x
Price/Cash Flow 40.1x
TEV/Sales 4.7x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MICROPORT SCIENTIFIC CORP, please visit www.microport.com.cn. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.